Chugai Pharmaceutical (OTCMKTS:CHGCY – Get Free Report) and Evolus (NASDAQ:EOLS – Get Free Report) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, valuation, earnings, analyst recommendations, profitability and risk.
Earnings and Valuation
This table compares Chugai Pharmaceutical and Evolus”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Chugai Pharmaceutical | $8.41 billion | 8.12 | $2.91 billion | $0.92 | 22.55 |
| Evolus | $297.18 million | 1.74 | -$51.64 million | ($0.52) | -15.08 |
Profitability
This table compares Chugai Pharmaceutical and Evolus’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Chugai Pharmaceutical | 35.09% | 23.76% | 19.92% |
| Evolus | -10.85% | N/A | -13.00% |
Analyst Recommendations
This is a summary of recent ratings for Chugai Pharmaceutical and Evolus, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Chugai Pharmaceutical | 0 | 3 | 1 | 1 | 2.60 |
| Evolus | 1 | 1 | 4 | 0 | 2.50 |
Evolus has a consensus target price of $14.50, indicating a potential upside of 84.95%. Given Evolus’ higher possible upside, analysts clearly believe Evolus is more favorable than Chugai Pharmaceutical.
Risk & Volatility
Chugai Pharmaceutical has a beta of 0.59, meaning that its share price is 41% less volatile than the S&P 500. Comparatively, Evolus has a beta of 1.42, meaning that its share price is 42% more volatile than the S&P 500.
Institutional & Insider Ownership
0.0% of Chugai Pharmaceutical shares are held by institutional investors. Comparatively, 90.7% of Evolus shares are held by institutional investors. 5.0% of Evolus shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Summary
Chugai Pharmaceutical beats Evolus on 10 of the 15 factors compared between the two stocks.
About Chugai Pharmaceutical
Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company’s products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng. It has various development product candidates in the areas of oncology, immunology, neuroscience, hematology, ophthalmology, and other diseases. Chugai Pharmaceutical Co., Ltd. has strategic alliances and collaboration with Roche Group. The company was founded in 1925 and is headquartered in Chuo, Japan. Chugai Pharmaceutical Co., Ltd. operates as a subsidiary of Roche Holding Ltd.
About Evolus
Evolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. It also provides dermal filler products under the Estyme and Evolysse names. The company was incorporated in 2012 and is headquartered in Newport Beach, California.
Receive News & Ratings for Chugai Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chugai Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.
